-Reuters Citing Interfax
Morgan Stanley Maintains Equal-Weight on Incyte, Raises Price Target to $77
Morgan Stanley analyst Vikram Purohit maintains Incyte (NASDAQ:INCY) with a Equal-Weight and raises the price target from $76 to $77.
Related Posts
GM CEO Mary Barra Says Company’s EV Strategy Remains On Track As Automaker Takes Steps To Cut Costs, Improve Margins
General Motors Co (NYSE: GM) reported better-than-expected financial results Tuesday morning, but the stock is hitting the brakes after the company announced cost-cutting measures, suggesting its EV strategy could face a bumpy road ahead
Luna Innovations Q4 EPS $0.08 Misses $0.09 Estimate, Sales $31.70M Miss $32.36M Estimate
Luna Innovations (NASDAQ:LUNA) reported quarterly earnings of $0.08 per share which missed the analyst consensus estimate of $0.09 by 11.11 percent. This is unchanged from the same period last year. The company reported